Atlas Trials

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Clinical trial NCT02226120 · COMPLETED

Trial details

NCT number
NCT02226120
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Chronic Heart Failure With Reduced Ejection Fraction
Start date
2014-10-16
Primary completion
2017-12-28
Enrollment
1980

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.